Hello,

Welcome to our flagship newsletter, MarketBeat Daily Ratings.

We'll deliver the latest "Buy" and "Sell" ratings from Wall Street's top-rated analysts directly to your inbox each morning.

But first, we need you to do two quick things:

1. Hit reply, and send a simple "Yes." Just one word. This tells Google (and other emails providers) that you actually want to get our newsletter.

2. After that, this link to confirm your subscription. That will tell us that you received our welcome email and that we should start sending your daily report. 

Confirm your subscription here.

After you have completed these two steps, we would like to gift you a free copy of one of our most popular investing reports: 7 Stocks to Buy and Hold Forever. You can download the report with this link.

Thank you again for subscribing. We look forward to being an important part of your investing journey

Matthew Paulson
Founder and CEO, MarketBeat.

P.S. If you didn’t intend to subscribe, no problem—you can unsubscribe with this link.

(ARReply-161)

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI

By Bridget Bennett. Publication Date: 10/8/2026.

The market has hit a record high, and almost none of that gain belongs to the average stock.

That gap is where Whitney Tilson of Stansberry Research is doing his shopping. His case is that the index is masking a broad bear market underneath and that the clearest values right now sit outside artificial intelligence. Three names make the case: a speculation, an off-the-radar mid-cap and the world's largest drugmaker.

A Record-High Index Is Masking a Market-Wide Bear Market

Here’s the stock symbol I’ve promised (Ad)

Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better.

This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.

Get the stock name and ticker symbol free of charge today

By Tilson's count, 19 of the 20 largest contributors to the S&P 500 this year are AI-related, and those names account for essentially the entire 13% index return. The other 480 stocks are collectively flat. Roughly 59% of S&P 500 components trade at least 20% below their all-time highs, and about one in six is down 50% or more.

That is what a bifurcated market looks like, and it is why a value investor staring at a 99th-percentile Shiller multiple can still have a long shopping list.

Tilson follows the old Buffett-Munger approach: estimate what a private buyer would pay for the whole business, then buy at a steep discount. The strategy requires the market to make mistakes, and a market this narrow makes plenty. ServiceNow (NYSE: NOW) was the recent example. Investors priced in agentic AI gutting enterprise software subscriptions, but large corporations declined to rip out systems that worked, and the stock recovered sharply.

Joby Aviation Is a Speculation With a Second Buyer Attached

Joby Aviation (NYSE: JOBY) builds an electric aircraft that takes off vertically and then rotates its motors forward to fly. It behaves like a helicopter but is roughly 99% quieter, which is the entire commercial argument: Most helicopters are not welcome over cities.

Tilson first recommended the stock near $7 three years ago. It tripled, then round-tripped back to about $7 and a $6 billion market cap. The caveats are significant: no revenue, no FAA approval and no commercial flights. This is a position to size carefully, not a core holding.

The market is pricing in a delay. Commercial service in the United Arab Emirates—a 30-minute hop between Abu Dhabi and Dubai—was delayed when regional conflict interrupted the timeline, and investors who saw no near-term catalyst sold. U.S. approval is realistically one to two years away, though Joby is further along than any competitor.

What could change sentiment is the first paying flight. What limits the downside is everything else the company owns: electric motor and battery technology, an engineering team and aircraft already delivered to the U.S. Air Force, where a silent airframe has obvious value. If air taxis never become a business, Tilson expects electric vehicle makers and defense contractors to engage in a bidding war.

Casey's General Stores Looks Like Walmart Did in 1988

Casey's General Stores (NASDAQ: CASY) operates about 3,000 convenience stores across 19 states from its Des Moines headquarters, generating roughly $18 billion in revenue against a $22 billion market cap. It is the third-largest convenience chain in the United States and the fifth-largest seller of pizza, which is the point: The high-margin "inside" business carries the model, and more than half of sales now run through the app.

The stock fell about 34% in two months, dropping from 35 times forward earnings to 26 times. The trigger was a quarter in which fuel margin drove the beat while in-store comps decelerated and management reaffirmed rather than raised guidance. At a premium multiple, reaffirming is not enough.

Nothing about the competitive position changed. Walmart (NYSE: WMT) generated the same $18.6 billion in trailing sales in mid-1988, with nearly identical profitability and a nearly identical forward multiple, and has since come close to being a 100-bagger. The comparison is not a forecast. It is a reminder that 26 times earnings is cheap for a business that can compound earnings at a double-digit rate for a decade. Casey's targets towns of 500 to 20,000 people, and Texas alone has roughly 2,000 of them.

Eli Lilly's Next Obesity Drug Is the Part the Market Is Discounting

Eli Lilly (NYSE: LLY) carries a trillion-dollar market cap and trades near 40 times trailing earnings, making it look like a story investors have already missed. Tilson believes the company is in the middle innings at most.

Two factors support that view. The first is retatrutide, Lilly's next-generation weight-loss candidate and the first to target three hormone receptors at once, rather than the two targeted by tirzepatide in Zepbound and Mounjaro. Average weight loss in trials has been closer to 29%, compared with roughly 20% for Zepbound, with less muscle loss. Lilly plans to file with the FDA in early 2027, putting a launch in late 2027 at the earliest.

The second is the size of the eventual market. Studies continue to reveal benefits beyond weight loss, including improvements in fatty liver disease, sleep apnea, inflammation, cholesterol and addictive behavior. The argument is that demand will eventually extend beyond people who need to lose weight, with low-dose use becoming common among people who do not.

Based on estimates Tilson believes are too conservative, Lilly trades near 28 times forward earnings, below where it has traded for most of the past few years.

Where the Risk and the Upside Sit

The risks are uneven. Joby can drift for quarters without a catalyst and burn goodwill along the way. Casey's needs in-store comps to stabilize because a fuel-led beat leaves guidance looking fragile. Lilly faces real pricing pressure across the category and a long regulatory runway before retatrutide sells a single dose.

The upside shares one trait: All three stocks sold off on sentiment rather than broken fundamentals, which is the only condition under which a value approach works at all.

Watch the catalysts instead of the quotes: Joby's first commercial flights, Casey's inside same-store sales and Lilly's retatrutide filing. Those are the developments that could move these three stocks.

For investors looking for more of Tilson's insights, visit here.